Meeting
2018 ASCO Annual Meeting
Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.
Authors
Arielle Medford
Massachusetts General Hospital, Boston, MA
Arielle Medford , Andrzej Niemierko , Beverly Moy , Laura Spring , Giuliana Malvarosa , Jerry Younger , Richard B. Lanman , Rebecca J Nagy , Ryan Bruce Corcoran , Steven J. Isakoff , Leif W. Ellisen , Dejan Juric , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 36, 2018 (suppl; abstr 1021)
DOI
10.1200/JCO.2018.36.15_suppl.1021
Abstract #
1021
Poster Bd #
102
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.
First Author: Justin Wayne Wong Tiu-lim
Poster
2022 ASCO Annual Meeting
Molecular characterization of NF1-mutated NSCLC and clinical outcomes.
First Author: Christopher Gates
Poster
2022 ASCO Annual Meeting
Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.
First Author: Mahesh Y. Iddawela
Poster
2017 ASCO Annual Meeting
Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.
First Author: Michael Boedigheimer